American technology entrepreneur and prominent longevity campaigner Bryan Johnson has disclosed his diagnosis with an incurable autoimmune disorder.
The 48-year-old, famous globally for his rigorous, multi-million-dollar anti-ageing endeavour known as Project Blueprint, confirmed he has autoimmune gastritis (AIG). This rare condition causes the body’s immune system to mistakenly attack the lining of the stomach.
Taking to the social media platforms, Johnson detailed his situation to his followers:
A history of hidden health issues
Johnson explained that his medical history includes a diagnosis of hypothyroidism at the age of 21 following a standard blood test. This early discovery allowed him to manage the thyroid condition proactively with daily hormone medication.
However, he was completely unaware that a secondary autoimmune response had begun targeting his stomach lining. Reflecting on his past, the biohacker pointed to a childhood filled with sugary cereals, fizzy drinks and fast food. While he enjoyed a brief period of good health in his early twenties, the pressures of raising three children and building a business eventually took a severe toll.
He noted that within a few years he had fallen into a deep depression, which is likely when the autoimmune process began to affect his thyroid and subsequently his stomach.
Uncovering the disease
The AIG diagnosis was only confirmed in May and Johnson admitted he is unsure exactly how long he has lived with the illness.
Over the last 11 years he had consistently recorded low ferritin levels without developing full-blown anaemia. Despite continuous efforts to boost his iron through diet and supplements, nothing proved effective. His medical team has only recently connected these early warning signs to AIG.
If left unmanaged, the disease can lead to irreversible damage including nutritional deficiencies, anaemia, an elevated risk of cancer over a long horizon
A biohacker’s approach to treatment
While standard medical practice generally views AIG as an incurable condition that can only be managed, Johnson remains committed to his ethos of «conquering death» and has pledged to find a solution.
Their experimental strategy involves rigorous routine monitoring of key biomarkers such as ferritin, iron, B12, gastrin and chromogranin A. He highlighted gastrin as a particularly crucial metric, noting that rising levels indicate disease progression and an increased risk of gastric neuroendocrine tumours.
Furthermore, Johnson’s medical team plans to conduct advanced characterisation of the illness. This will include repeat biopsies, deep cytokine profiling and T-cell subset analysis to determine exactly how the disease operates. These specific findings will then directly shape an experimental intervention plan.
Understanding autoimmune gastritis
The Global Autoimmune Institute defines AIG as a rare inflammatory disease where antibodies mistakenly destroy the acid-producing cells within the stomach lining.
While frequently asymptomatic in its initial phases, patients may eventually experience a range of disruptive symptoms. These can include upper abdominal pain, heartburn, bloating, feeling full rapidly, fatigue, shortness of breath, weakness, sensory changes and balance issues.
